Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Boehringer Ingelheim
Express Scripts
Mallinckrodt
Dow

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204708

See Plans and Pricing

« Back to Dashboard

NDA 204708 describes MIRVASO, which is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug and one Paragraph IV challenge. Additional details are available on the MIRVASO profile page.

The generic ingredient in MIRVASO is brimonidine tartrate. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
Summary for 204708
Tradename:MIRVASO
Applicant:Galderma Labs Lp
Ingredient:brimonidine tartrate
Patents:12
Pharmacology for NDA: 204708
Mechanism of ActionAdrenergic alpha-Agonists
Medical Subject Heading (MeSH) Categories for 204708
Suppliers and Packaging for NDA: 204708
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MIRVASO brimonidine tartrate GEL;TOPICAL 204708 NDA Galderma Laboratories, L.P. 0299-5980 0299-5980-00 1 TUBE in 1 BLISTER PACK (0299-5980-00) > 2 g in 1 TUBE
MIRVASO brimonidine tartrate GEL;TOPICAL 204708 NDA Galderma Laboratories, L.P. 0299-5980 0299-5980-02 2 g in 1 TUBE (0299-5980-02)
Paragraph IV (Patent) Challenges for 204708
Tradename Dosage Ingredient NDA Submissiondate
MIRVASO GEL;TOPICAL brimonidine tartrate 204708

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:GEL;TOPICALStrengthEQ 0.33% BASE
Approval Date:Aug 23, 2013TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Jun 13, 2031Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Aug 25, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
Patent:  Start TrialPatent Expiration:Jun 13, 2031Product Flag?YSubstance Flag?Delist Request?
Patented Use:TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Moodys
Boehringer Ingelheim
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.